Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5893-5899

  Veal, Gareth J ^a   Cole, Michael ^a   Errington, Julie ^a   Parry, Annie ^a   Hale, Juliet ^a   Pearson, Andrew D J ^a   Howe, Karen ^b   Chisholm, Julia C ^b   Beane, Carol ^c   Brennan, Bernadette ^c   Waters, Fiona ^d   Glaser, Adam ^d   Hemsworth, Sue ^e   McDowell, Heather ^e   Wright, Yvonne ^f   Pritchard Jones, Kathy ^f   Pinkerton, Ross ^f   Jenner, Gail ^g   Nicholson, James ^g   Elsworth, Ann M ^h   Boddy, Alan V ^a,i   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DATA ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; EYE INFECTION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SKIN TOXICITY; SURFACE PROPERTY; THROMBOCYTOPENIA; UNITED KINGDOM;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HUMANS; IFOSFAMIDE; INFECTION; INFUSIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; NEOPLASMS; TIME FACTORS;

EID: 23844488773     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2546     Document Type: Article

References (17)

1. Green DM. Wilms' tumour. Eur J Cancer 1997;33:409-18.
2. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:3744-51.
3. Mitchell C, Jones PM, Kelsey A, et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 2000;83:602-8.
4. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric OncologyWilms' Tumor Trial and Study. J Clin Oncol 2001;19:488-500.
5. Arndt C, Hawkins D, Anderson JR, Brietfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, andcyclophosphamide. J Clin Oncol 2004;22:1894-901.
6. Green DM, Norkool P, Breslow NE, Finklestein JZ, D'Angio GJ. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 1990;8:1525-30.
7. Davidson A, Pritchard J. Actinomycin D, hepatic toxicity and Wilms' tumour - a mystery explained? Eur J Cancer 1998;34:1145-7.
8. D'Antiga L, Baker A, Pritchard J, Pryor D, Mieli-Vergani G. Veno-occlusive disease with multi-organ involvement following actinomycin D. Eur J Cancer 2001;37:1141-8.
9. Tattersall MHM, Sodergren JE, Sengupta SK.Trites DH, Modest EJ, Frei E. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975;17:701-8.
10. Brothman A. Development of an antibody to actinomycin D and its application for the detection of serum levels by radioimmunoassay. Cancer Res 1982;42:1184-7.
11. Fujiwara K, Saita T, Takenawa N, Matsumoto N, Kitagawa T. Enzyme-linked immunosorbent assay for the quantification of actinomycin D using β-D-galactosidase as a label. Cancer Res 1988;48:4843-7.
12. Saunders GC, Martin JC, Jett JH, Perkins A. Flow cytometric competitive binding assay for determination of actinomycin D concentrations. Cytometry 1990;11:311-3.
13. Veal GJ, Errington J, Sludden J, et al. Determination of anticancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B 2003;795:237-43.
14. Boeckmann A, Beal SL, Sheiner LB. Technical report of the Division of Clinical Pharmacology, in NONMEM users manual V5; 1997.
15. Yung BY-M, Bor AM-S, Chang P-K. Short exposure to actinomycin D induces reversible translocation of protein B23 as well as reversible inhibition of cell growth and RNA synthesis in HeLa cells. Cancer Res 1990;50:5987-91.
16. Jones B, Breslow NE, Takashima J. Toxic deaths in the second National Wilms' Tumour Study. J Clin Oncol 1984;2:1028-33.
17. Morgan E, Baum E, Breslow N, Takashima J, D'Angio G. Chemotherapy-related toxicity in infants treated according to the Second National Wilms' Tumor Study. J Clin Oncol 1988;6:51-5.